Dexcom (DXCM) EBT (2010 - 2026)

Dexcom (DXCM) has reported EBT for 17 consecutive years, with $317.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 31.69% year-over-year to $317.5 million in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 63.24% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 53.51% from the prior year.
• EBT was $317.5 million for Q2 2026 at Dexcom, up from $269.5 million in the prior quarter.
• Over five years, EBT peaked at $352.3 million in Q3 2025 and troughed at $36.1 million in Q1 2022.
• A 5-year average of $193.6 million and a median of $182.6 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT jumped 1981.25% in 2022 and decreased 26.21% in 2024, its largest moves.
• Over 5 years, EBT stood at $133.2 million in 2022, then surged by 84.83% to $246.2 million in 2023, then retreated by 14.18% to $211.3 million in 2024, then soared by 61.24% to $340.7 million in 2025, then slipped by 6.81% to $317.5 million in 2026.
• The last three EBT figures came in at $317.5 million (Q2 2026), $269.5 million (Q1 2026), and $340.7 million (Q4 2025), per Business Quant data.